Merit Medical names Martha Aronson CEO, replacing Fred Lampropoulos effective October 3, 2025
Merit Medical Systems appointed Martha G. Aronson as President and CEO effective October 3, 2025, succeeding Fred P. Lampropoulos, who remains Chairman of the Board. The board also expanded its size from ten to eleven directors and added Ms. Aronson to the board, a leadership change that matters to shareholders as it sets a new chief executive direction.
Key points
- Martha G. Aronson becomes President and CEO and a director effective October 3, 2025.
- Fred P. Lampropoulos resigned as CEO and will serve as Executive Chairman until January 3, 2026, then remain a director and Chairman.
- Ms. Aronson's offer letter includes a $1,000,000 base salary, a $250,000 signing bonus, and a target bonus of 100% of base salary.
- Her initial equity award has a target grant date fair value of $5,500,000, and an upfront equity grant of $4,125,000 is planned.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.